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Abstract : Doripenem （DRPM） is a relatively new drug belonging to the carbape-
nem antibiotic group.  We hypothesized that the pharmacological characteristics of 
DRPM could make it useful in the treatment of severe acute pancreatitis （SAP）.  
We investigated the usefulness of continuous regional arterial infusion （CRAI） 
with DRPM and protease inhibitors for SAP.  Two hundred and forty-two patients 
with SAP were admitted to Showa University Hospital between November 2002 
and June 2013.  Of these, 53 patients were treated with CRAI with carbapenem 
antibiotics and nafamostat mesilate （NM）, a serine protease inhibitor, via the celiac 
and superior mesenteric arteries.  Clinical outcomes were evaluated retrospectively 
in 34 patients treated with DRPM and 19 patients undergoing non-DRPM therapy 
（meropenem n＝11, imipenem n＝6 ; biapenem n＝2）.  The median time to 
commencement of oral intake was significantly shorter in the DRPM than non-
DRPM group （9 vs 14 hospital days, respectively ; P＜0.01）.  In addition, the rate 
of walled-off necrosis in the DRPM group tended to be lower than in the non-
DRPM group （37.5 vs 64.7％, respectively, P＝0.069）.  The results of the present 
study suggest that CRAI with DRPM and NM for SAP could have equivalent 
therapeutic effects to CRAI with other carbapenem antibiotics and NM.
Key words : continuous regional arterial infusion, doripenem, protease inhibitor, 
severe acute pancreatitis
Introduction
　Severe acute pancreatitis （SAP）, although a benign disease, is associated with high mortal-
ity and is often refractory to treatment.  The mortality rate of SAP has been reported to be 
approximately 30％1）.
　Guidelines regarding pancreatitis have been amended using a revision of the Atlanta Interna-
tional Classication2）.  In these new guidelines, the denition, severity assessment, and treatment 
strategies for SAP have been revised.  SAP is diagnosed when there is associated organ failure 
that is refractory to therapy for 48 hr.
　In current practice, patients are observed for 4 weeks for the development of walled-off necro-
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sis （WON）, a complication of infectious pancreatitis, which, if it occurs, is then treated by the 
recommended therapeutic approach of necrosectomy using a low invasive approach 3）.  Infectious 
pancreatic complications are an important prognostic factor for SAP ; it is reported that continu-
ous regional arterial infusion （CRAI） with antibiotics and protease inhibitors is effective in 
preventing infectious pancreatic complications and reducing mortality following SAP 4, 5）.  Recently, 
studies have been published describing CRAI with carbapenem antibiotics 6-11）.  Based on the 
results of these studies, we adopted CRAI with carbapenem antibiotics and protease inhibitors 
for the treatment of SAP.  SAP is associated with a high mortality rate.  Therefore, it is very 
difcult to perform a prospective study for SAP.
　The aim of the present study was to evaluate the usefulness of CRAI with doripenem 
（DRPM） and the serine protease inhibitor nafamostat mesilate （NM） for SAP.  DRPM is a 
relatively new drug belonging to the carbapenem antibiotic group.  We hypothesized that the 
pharmacological characteristics of DRPM could make it useful in the treatment of SAP.  We 
compared the safety and efficacy of CRAI with DRPM and NM for SAP with non-DRPM 
therapy （i.e. treatment with other carbapenem antibiotics） by assessing adverse events and the 
mortality of SAP following treatment.
Material and methods
　Two hundred and forty-two patients with SAP were admitted to Showa University Hospital 
between November 2002 and June 2013.  Of these, 53 patients underwent treatment with CRAI 
with carbapenem antibiotics and NM via the celiac and superior mesenteric arteries.  Clinical 
outcomes, such as infectious complications and mortality, were reviewed retrospectively and com-
pared between the 34 patients who received DRPM and the 19 patients who were treated with 
non-DRPM therapy （meropenem ［MEPM］ n＝11 ; imipenem ［IPM］ n＝6］; biapenem ［BIPM］ 
n＝2）.
　In Japan, the prognostic factors and computed tomography （CT） grading for acute pancreati-
tis 12）, developed by the Research Committee of Intractable Diseases of the Pancreas （Ministry 
of Health, Labour and Welfare）, are used for the assessment of the severity of acute pancreatitis 
（Table 1）.
　CRAI was used in patients with severe acute necrotizing pancreatitis, dened as a lack of 
enhancement of pancreatic parenchyma on contrast-enhanced （CE） CT.  The drugs administered 
by CRAI were NM （240 mg / day） together with either 1.5 g / day DRPM （0.5 g every 8 hr）, 
2 g / day MEPM （1 g every 12 hr）, 2 g / day IPM （1 g every 12 hr）, or 1.2 g / day BIPM （0.6 g 
every 12 hr）.  The antibiotic used was chosen at the discretion of the attending physician.
　Continuous variables are expressed as median values with the range in parentheses.  Statistical 
analyses were performed using StatMate III software （ATMS, Tokyo, Japan）.  Data were ana-
lyzed by the Mann–Whitney U-test and Chi-squared test, with P＜0.05 considered signicant.
　The present retrospective study was approved by the Ethics Committee of Showa University 
Hospital.
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Results
　The median age of the 53 SAP patients （41 men, 12 women） was 49 years （range 15～ 85 
years）.  Disease etiology included alcoholic pancreatitis in 34 patients, gallstones in two, idio-
pathic pancreatitis in 13, and other diseases in the remaining four patients.  The median Japanese 
prognostic factors score within 48 hr of admission was 4 points （range 0～ 8 points）.  CE-CT 
Grade 2 disease was present in 30 patients, whereas Grade 3 disease was present in 23 patients. 
The median Acute Physiology and Chronic Health Evaluation （APACHE） II score was 10 
points （range 0～ 31 points）, and the median sequential organ failure assessment （SOFA） score 
was 2 points （range 0～ 10 points）.  The median day of commencement of CRAI was Hospital 
Day 1 （range Days 1～ 4）, the median duration of CRAI was 5 days （range 3～ 7 days）, and 
the mortality rate was 9.4％.
　There were no signicant differences in patient characteristics between the DRPM and non-
DRPM groups in terms of age, sex, etiology, Japanese prognostic factors score, CE-CT grade, 
APACHE-II score, SOFA score, starting day of CRAI, and duration of CRAI （Table 2）.  No 
Table 1.  Japanese severity scoring system for acute pancreatitis （Ministry of Health, Labour and 
Welfare of Japan, 2008 revision）
Prognostic factors （1 point for each factor）
1. Base excess ≤-3 mEq / l or shock （systolic blood pressure ＜80 mmHg）
2. PaO2 ≤ 60 mmHg （room air） or respiratory failure （requiring ventilatory management）
3.  BUN ≥ 40 mg / dl or creatinine ≥ 2.0 mg / dl or oliguria （daily urine output ＜400 ml even 
after intravenous fluid resuscitation）
4. Lactate dehydrogenase ≥ 2 ULN
5. Platelet count ≤ 100,000/mm3
6. Serum Ca ≤ 7.5 mg / dl
7. C-Reactive protein ≥ 15 mg / dl
8. No. positive measures in SIRS criteria ≥ 3
9. Age ≥ 70 years
CT grade based on contrast-enhanced CT
1 Extrapancreatic progression of inflammation
 Anterior pararenal space 0 points
 Root of mesocolon 1 point
 Beyond lower pole of kidney 2 points
2. Hypo-enhanced lesion of the pancreas
 The pancreas is conveniently divided into three segments （head, body, and tail）
Localized in each segment or only surrounding the pancreas 0 points
Extends to two segments 1 point
Occupies entire two segments or more 2 points
 1＋ 2＝ total score
   Total score＝ 0 or 1 Grade 1
   Total score＝ 2 Grade 2
   Total score ≥ 3 Grade 3
Assessment of severity
If the prognostic factors score is ≥ 3 or CT grade is ≥ 2, the disease is graded as ‘severe’
　The systemic inflammatory response syndrome （SIRS） criteria include body temperature ＞38℃ 
or ＜36℃, heart rate ＞90 b.p.m., respiratory rate ＞20 breaths / min or PaCO2 ≤ 32 torr, and white 
blood cell counts ＞12,000 cells / mm3, ＜4000 cells / mm3, or ＞10％ immature （band） forms.
　BUN, blood urea nitrogen ; ULN, upper limit of normal ; CT, computed tomography.
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signicant differences were observed between the two groups with regard to the disappearance of 
abdominal pain, duration of administration of antibiotics, early organ dysfunction rate, late severe 
infection rate, surgery rate, duration of admission, and mortality.  The median day of commence-
ment of oral feeding was signicantly earlier in the DRPM than non-DRPM group （9 vs 14 
hospital days, respectively ; P＜0.01）.  The rate of WON tended to be lower in the DRPM than 
non-DRPM group （37.5％ vs 64.7％, respectively ; P＝0.069 ; Table 3）.  Adverse events due to 
CRAI with DRPM and NM for SAP included increased serum bilirubin levels in ve patients 
（two patients had increased aspartate aminotransferase and alanine aminotransferase levels）, one 
case of subarachnoid hemorrhage （SAH）, and one case of obstruction of the artery of the lower 
extremity.
Discussion
　When acute pancreatitis is suspected, its severity needs to be determined so that appropriate 
treatment can be administered.  In severe cases, strict circulatory and respiratory management are 
necessary.
　In Showa University Hospital, CRAI is performed in patients with severe acute necrotizing 
pancreatitis, and continuous hemodialtration （CHDF） is performed in patients with SAP with 
organ dysfunction.  Further, we provide early enteral nutrition as infection prophylaxis for SAP.
　In Japan, it is not considered necessary to administer antibiotics prophylactically to patients 
with mild acute pancreatitis because of the low rate of infectious complications and mortal-
ity.  Although prophylactic administration of antibiotics for SAP can improve the prognosis and 
decrease the incidence of infectious pancreatic complications, it is necessary to consider the 
antibacterial spectrum, pancreatic tissue concentration, and dosing period of antibiotics for SAP. 
Table 2.  Patient characteristics in doripenem （DRPM）-treated and -untreated （non-DRPM） patients
DRPM
group （n＝34）
Non-DRPM
group （n＝19） P value
Age （years） 51 （19～ 85） 48 （15～ 83） NS
No. men / women 27 / 7 14 / 5 NS
Etiology （alcohol / gallstones / idiopathic / others） 24 / 1 / 7 / 2 10 / 1 / 6 / 2 NS
Japanese prognostic factors score （points） 3 （0～ 7） 4 （1～ 8） NS
CE-CT grade （1 / 2 / 3） 0 / 22 / 12 0 / 8 / 11 NS
APACHE-II score （points） 11 （0～ 28） 9 （1～ 31） NS
SOFA score （points） 3 （0～ 10） 2 （0～ 10） NS
Start time of CRAI （hospital day） 1 （1～ 3） 1 （1～ 4） NS
Duration of CRAI （days） 5 （3～ 5） 5 （3～ 7） NS
Data are presented as median values with the range in parentheses, or as the number of patients in each group.
CE-CT, contrast-enhanced computed tomography ; APACHE, Acute Physiology and Chronic Health Evaluation ; 
SOFA, Sequential Organ Failure Assessment ; CRAI, continuous regional arterial infusion.
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Interestingly however, one published study in 2006 does not recommend prophylactic antibiotic 
therapy in patients with SAP 13）.
　Buchler et al 14） examined pancreatic tissue concentrations of different antibiotics and reported 
that imipenem （carbapenem antibiotics）, ofloxacin, and ciprofloxacin （new quinolone） had 
high pancreatic tissue concentrations and extensive bactericidal activity against most bacteria. 
Therefore, we examined the usefulness of prophylactic antibiotics in SAP in the present study. 
There have been some reports published regarding the prophylactic use of antibiotics for severe 
pancreatitis 15-26）.  The efcacy of prophylactic antibiotics for acute pancreatitis was rst reported 
after the introduction of carbapenem antibiotics in the 1990s, including a report regarding the use 
of imipenem by Pederzoli et al 15）.  Recently, carbapenem antibiotics for SAP have been recom-
mended in Japan 7-10）.
　Some placebo-controlled double-blind studies have evaluated transvenous prophylactic antibiotic 
therapy 21, 22）.  These studies suggest that prophylactic antibiotic therapy for SAP does not neces-
sarily lead to decreases in infectious pancreatic complications and mortality rate.  However, these 
studies varied in the type of antimicrobial agent used, the route of administration, and the day 
on which antibiotics were started.  Therefore, denying early prophylactic antibiotic therapy based 
on these studies is not appropriate.
　Conversely, a randomized controlled trial （RCT） on early prophylactic antibiotic therapy for 
SAP reported decreases in infectious pancreatic complications and mortality rate with such 
therapy 25）.  Manes et al 22） conducted an RCT using MEPM for necrotizing pancreatitis.  They 
divided patients into two groups based on the timing of commencement of antibiotic administra-
tion （i.e. at admission and after CE-CT conrmation of the pancreatic necrotic area）.  Pancreatic 
infection occurred in 13％ of patients in the former group, compared with 31％ of patients in 
Table 3.  Clinical outcomes in doripenem （DRPM）-treated and -untreated （non-DRPM） patients
DRPM 
group （n＝34）
Non-DRPM 
group （n＝19） P value
Disappearance of abdominal pain （hospital day） 5 （2～ 12） 5 （3～ 15） NS
Start day of oral intake （hospital day） 9 （4～ 35） 14 （10～ 93） ＜0.01
Duration of administration of antibiotics （days） 12 （3～ 57） 13 （3～ 143） NS
Early organ dysfunction rate 64.7％ （22 / 34） 84.2％ （16 / 19） NS
Late severe infection rate 13.3％ （4 / 30） 17.6％ （3 / 17） NS
Surgery rate 2.9％ （1 / 34） 5.3％ （1 / 19） NS
WON rate 37.5％ （12 / 32） 64.7％ （11 / 17） NS （0.069）
Duration of admission （days） 21 （3～ 115） 25 （3～ 172） NS
Mortality rate 8.8％ （3 / 34） 10.5％ （2 / 19） NS
Data are given as median values with the range in parentheses, or as percentages with the number of patients /
total number of patients in parentheses.
WON, walled-off necrosis.
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the latter group, with extrapancreatic infection observed in 17％ and 45％ of patients, respectively. 
Pancreatic and extrapancreatic infection rates in the former group were signicantly lower than 
in the latter group.  In addition, the former group had lower surgery rates and a shorter period 
of admission than patients in the latter group.  Therefore, the results of the study of Manes 
et al 22） suggest that the time of initiation of antibiotic therapy is an important determinant of 
patient outcome.
　CRAI for acute necrotizing pancreatitis was reported by Takeda et al 4）, and came to be 
recognized as appropriate therapy for SAP.  The purpose of CRAI is to directly deliver a high 
concentration of the protease inhibitor and antibiotic to the site of inammation and necrotic tis-
sue by intra-arterial injection to prevent local pancreatic inammation and infection.  NM acts as 
a protease inhibitor at low concentrations and as an anticoagulant at high concentrations.  It is 
estimated that local pancreatic concentrations of drugs administered by intra-arterial injection for 
CRAI can reach levels nine fold higher, or more, than those seen after intravenous infusion 27）. 
Takeda et al 4） reported that NM inhibits the extension of pancreatic necrosis by its anticoagulant 
action in the microcirculation, and is effective for the prevention of vasospasm and vascular 
occlusion.  In that study, intraperitoneal infections, infections due to pancreatic necrosis, and mor-
tality were signicantly lower in the NM than non-NM group.
　Hayashi et al 6） have reported the usefulness of CRAI via the celiac artery, whereas Takagi 
and Isaji 5） have reported the usefulness of CRAI via the superior mesenteric artery. 
　In studies that divided patients with SAP into CRAI and non-CRAI groups, infectious pancre-
atic complications, surgical rate, and mortality were lower in the CRAI than non-CRAI group 7, 8）. 
It has also been reported that patients who received CRAI for SAP with gabexate mesilate as 
the protease inhibitor had a shorter duration until the disappearance of abdominal pain, lower 
systemic inammatory response syndrome （SIRS） positive scores, and a shorter duration of hos-
pitalization than patients in the non-CRAI group 9）.
　Ishikawa et al 10） reported on the usefulness of CRAI with NM and IPM for SAP.  The 
mortality rate was signicantly lower in the group that started CRAI within 3 days of the onset 
of SAP compared with the group that started CRAI after 3 days after onset （0％ vs 66.7％, 
respectively）.  Ishikawa et al 10） concluded that the timing of CRAI initiation is extremely impor-
tant, and that CRAI should be initiated within 3 days of the onset of SAP for greater efcacy.
　An RCT of CRAI for SAP was rst reported by Piascik et al 11）.  In that study, 78 patients 
were randomly divided within 72 hr from the onset of acute pancreatitis and hospitalization into 
two groups （n＝39 in each）: a CRAI group and a non-CRAI group.  The CRAI group was 
treated continuously with 240 mg / day NM and 1 g / day IPM for 5 days as an arterial infusion 
via one of the arteries perfusing the pancreas, following which IPM was given intravenously 
（0.5 g every 8 hr） for at least 9 days.  The non-CRAI group received IPM （0.5 g every 8 hr） 
intravenously for 14 days.  The mortality rate was lower in the CRAI than non-CRAI group, 
indicating that CRAI for SAP with a protease inhibitor and antibiotic is effective in preventing 
adverse events and reducing mortality rates.
　Recently, a pharmacokinetic–pharmacodynamic theory was proposed 28, 29）.  β-Lactam antibiotics, 
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such as carbapenem antibiotics, are drugs with time-dependent bactericidal activity.  In vivo, the 
proliferative inhibitory effect and maximal bactericidal action correlate with the time for which 
the drug concentration exceeds its minimum inhibitory concentration （MIC ; ％T＞MIC）.
　In the present study, we chose DRPM as the antibiotic to be evaluated for the following 
reasons : （1） DRPM is highly effective against aerobic Gram-negative and Gram-positive bacteria, 
as well as anaerobic bacteria, and it suppresses the growth of antimicrobial-resistant Pseudomonas 
aeruginosa ; （2） DRPM, MEPM, and IPM exhibit potent activity, with an MIC90 of 4, 16, and 
32 µg / ml, respectively, and DRPM is clinically effective against P. aeruginosa infection ; （3） DRPM 
does not show any cross-resistance with MEPM and IPM against P. aeruginosa ; （4） incompat-
ibility between DRPM and protease inhibitors is low ; and （5） DRPM is a drug with little effect 
on the central nervous system30-36）.
　In addition, on the basis of changes in plasma concentrations in healthy adults in a Phase I 
study 14）, it has been suggested that as the number of doses of DRPM increases, the time above 
the MIC of DRPM increases.  In the present study, the incidence of WON in the DRPM group 
tended to be lower than in the non-DRPM group, indicating the clinical efcacy of CRAI with 
DRPM and NM.  One study compared the MIC90 of DRPM, IPM, and MEPM for the main 
microorganism strains affected by them.  In most strains, the MIC90 of DRPM was lower than 
that of IPM and MEPM 29）.
　In the present study, it is possible that synergistic actions between DRPM and NM led to the 
observed decrease in the incidence of WON.
　In conclusion, the results of the present study suggest that CRAI with DRPM and NM for 
SAP could provide equivalent therapeutic effects to those seen following CRAI with other car-
bapenem antibiotics and NM.
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